Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?
Giembycz
M A
MA
Department of Thoracic Medicine, Royal Brompton National Heart and Lung Institute, London, U.K.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000517:prevention & control; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004804:Eosinophils / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000517:prevention & control; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008264:Macrophages / Q000187:drug effects; D008407:Mast Cells / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects
D001993:Bronchodilator Agents; D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D015105:3',5'-Cyclic-AMP Phosphodiesterases